Eli Lilly and Company (LLY)
Verdict history · LLY
Every call Verdix has made on LLY.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
Click any date below to read that write-up
Three weeks ago the panel said WAIT and named $1,249.45 as the breakout trigger; that level has now been decisively cleared on a weekly close at $1,255.40, so the trigger fired. The shift from WAIT to BALANCED reflects that the technical condition for a bullish entry has been met, but the fundamental picture has not improved enough to justify fresh buying at the higher price — the business is the same great business, only it now costs 6.4% more, and two of five voices now decline to endorse the entry at these levels.
See methodology for how verdicts are produced. Full track record →
The panel’s split verdict on LLY — and where they disagree.
The case for and against roughly balance — no clear edge at today's price.
NYSE · Health Care / Pharmaceuticals · 2026-08-22 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
BalancedMEDIUM confidence
Why
Eli Lilly's GLP-1 franchise is firing on all cylinders — Mounjaro revenue up 91%, oral Foundayo doubling monthly, Medicare obesity coverage just beginning — but the stock has risen 6.4% in three weeks to $1,255, and the panel now splits between those who see a fair price for a great business and those who see no margin of safety at 42x earnings. The call is BALANCED: existing shareholders should let the trend work, while fresh money should wait for a pullback into the $1,124–$1,151 support band or a competitive shock that resets the multiple.Level to watch
Key support 1,249.45−0.5% from 1,255.4
Next catalyst
Pullback zone to watch: A retracement into the $1,124–$1,151 band (weekly EMA20 to the 23.6% Fibonacci level) would restore a margin of safety without breaking the Stage 2 uptrend and would flip the panel's call to BUY.The panel's take
Verdict: BALANCED · Conviction: MEDIUM · Last price: 1255.4 · Changed from WAIT
Panel: 2 Bullish · 2 Neutral · 1 Bearish → BALANCED
What changed since 2026-08-15:
- Price: 1180.16 → 1255.4 (+6.38%)
- Panel: 2 of 7 → 2 of 5 now Bullish — composition also changed: added none; removed The Asymmetric Bargainer, The Quality Rationalist
- Trigger: BUY on a pullback into the $1,124–$1,151 support band (weekly EMA20 to the 23.6% Fib retracement that was the prior-trigger's pullback target, now the nearest meaningful support below the breakout) — a correction that restores margin of safety without breaking the uptrend. SELL if price closes a week below $1,028 (weekly EMA50), invalidating the Stage 2 structure, or if a competitor's oral GLP-1 materially compresses net margins below 30%.
- Verdict: WAIT → BALANCED
Three weeks ago the panel said WAIT and named $1,249.45 as the breakout trigger; that level has now been decisively cleared on a weekly close at $1,255.40, so the trigger fired. The shift from WAIT to BALANCED reflects that the technical condition for a bullish entry has been met, but the fundamental picture has not improved enough to justify fresh buying at the higher price — the business is the same great business, only it now costs 6.4% more, and two of five voices now decline to endorse the entry at these levels.
BALANCED with medium confidence. Three weeks ago we said WAIT and named $1,249.45 as the breakout trigger. That level has been decisively broken on the weekly close ($1,255.40), so the trigger FIRED and our neutral stance on new entries no longer holds — for existing holders the trend is intact, but fresh buying at 42x earnings 3% below the all-time high is a different proposition. Four of five voices acknowledge the business is exceptional (Mounjaro +91%, Foundayo accelerating, Medicare tailwind just beginning); two — The Forensic Skeptic on price, The Disruptive-Innovation Seeker on the GLP-1 story being late-stage rather than early — decline to get bullish at these levels. The resulting split is 2 Bullish / 2 Neutral / 1 Bearish, which arithmetic converts to BALANCED: a great company at a price that already demands a great outcome.
Key levels
Key levels · LLY
USD · as of 2026-08-22Analyst consensus target 1,311 USD · range 850–1,600
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key resistance is the all-time high at $1,292.65, tested and rejected once already — a weekly close above it would confirm the breakout into price discovery. Key support sits at the just-cleared $1,249.45 (former horizontal resistance, now first support on any dip) and the $1,124.48 weekly EMA20, which price has not closed below during the current advance. The $1,028.49 weekly EMA50 is the Stage 2 floor — price above it keeps the multi-year uptrend intact. The analyst consensus target of $1,311 sits 4.4% above the current price, bracketed by the $1,292.65 ATH below and the $1,372 median target above — a narrow band of expected upside that reinforces why the panel is not chasing here.
What legendary investors think
We ran Eli Lilly and Company past a panel of 5 legendary investors' frameworks.
The panel · 5 investors
The GARP OperatorGrowth (GARP)🟢 BullishMed
Signal: Mounjaro revenue surged 91% in Q2 and the newly launched oral pill Foundayo is doubling prescriptions monthly, against a forward P/E of 30.78 and a PEG of 1.46, which is reasonable for a wide-moat compounder still delivering 30% EPS growth into a Medicare obesity-coverage tailwind that just began. Conviction: Conviction stays at 65% because net debt of $45 billion and a debt/equity ratio of 1.62 sit uneasily with what this framework demands of a fast grower — strong top-line momentum earns a premium, but the stretched balance sheet keeps it from being a clean story.
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralLow
Signal: The base-case DCF, anchored to 25% revenue growth for three years before fading to 12% and terminal 3%, lands near $1,200 — roughly flat against the current $1,255 — which means years of exceptional execution are already priced into the share count with no margin of safety. Conviction: Conviction sits at just 45% because the wide $850-to-$1,650 scenario range is driven by a single unresolved dependency: whether operating margins can reach 40% before oral-GLP-1 competition forces price concessions.
The Disruptive-Innovation SeekerDisruptive Innovation🔴 BearishLow
Signal: The GLP-1 S-curve is in Early Majority, not Early Adoption, and key patents begin expiring in 2030–2032, well inside the 5-year horizon, which means the exponential-growth chapter is behind the stock even as consensus extrapolates 48% revenue gains indefinitely. Conviction: Conviction is capped at 45% by the absence of a platform-level technology: GLP-1s are a successful application of known biology, not a CRISPR-like innovation whose cost curve would create new demand pools, and without that dynamic the 42x multiple depends entirely on a pricing-power assumption that CEO Ricks himself is already walking back.
The Scuttlebutt Growth InvestorGrowth/Management🟢 BullishMed
Signal: The 15-point checklist scores 13 out of 15, with the only gaps being unratable labor-relations data, while Lilly holds 60.9% of the U.S. obesity-diabetes GLP-1 market, management speaks with candor about pricing dynamics, and the Medicare tailwind is just beginning to compound. Conviction: Conviction reaches 78% because multiple independent signals — market-share dominance, accelerating oral adoption, raised guidance, and a CEO with a multi-year track record of delivering on promises — reinforce the thesis from different angles with very few dependencies that could break it.
The Forensic SkepticContrarian/Forensic⚫ NeutralLow
Signal: At 42x trailing earnings and 33x book value, with net debt issuance accelerating to $15.2 billion TTM and historical OCF-to-net-income running at just 0.81–0.83x during the growth ramp, the stock is priced for a perfect outcome while the balance sheet is being stretched to fund it. Conviction: Conviction is held to 35% because the margin of safety is negative under every valuation method applied — the $850-to-$1,100 intrinsic-value range sits well below the current quote — and the only thing that would close the gap is another year of unreplicated 48% revenue growth, which is a fragile single-thread assumption.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- The business itself is exceptional: Mounjaro/Zepbound is a genuine blockbuster franchise, the oral GLP-1 Foundayo is accelerating, and Medicare coverage for obesity is a structural tailwind that is only beginning to unfold.
- Management quality and commercial execution are both rated highly — CEO Ricks communicates with candor, the company holds 60.9% U.S. GLP-1 market share, and the beat-and-raise pattern in recent quarters is backed by real demand, not accounting gimmicks.
- The balance sheet is leveraged and getting more so: net debt of roughly $45 billion, debt/equity at 1.62x, and TTM capex plus acquisitions approaching $25 billion mean the company is committing enormous capital to lock in its manufacturing lead before competition arrives.
- At $1,255 — up 6.4% from three weeks ago and 3% below the all-time high — price is the central friction: everyone agrees the company is high-quality, and the disagreement is entirely about whether the current multiple leaves enough room for the investment to compound.
The real debate
- The Scuttlebutt Growth Investor sees 60.9% market share, 48% revenue growth, and a Medicare tailwind just starting and concludes the growth story is still early, while The Disruptive-Innovation Seeker sees the same data and concludes the S-curve is in Early Majority with a patent cliff arriving within the 5-year horizon — both are reading the same facts through different timeframes.
- The GARP Operator accepts a PEG of 1.46 as reasonable for a 30% grower with a wide moat, but The Forensic Skeptic counters that the multiple on tangible book (161x) and the negative margin of safety under every valuation framework make the stock uninvestable regardless of how good the business is.
- The Intrinsic-Value Modeler's base case lands near fair value, implying BALANCED, but the $850 bear case and $1,650 bull case hinge entirely on one contested assumption: whether 40%+ operating margins are achievable before oral-GLP-1 competition from Novo Nordisk, Roche, and Amgen forces pricing discipline.
The question it comes down to: Is Eli Lilly's GLP-1 franchise still in the early innings of a decades-long growth run, with manufacturing scale and oral formulations creating a compounding moat — or is the market already pricing in the best-case scenario at 42x earnings, leaving no room for the competition and patent expiry that arrive within the investment horizon?
The bottom line
- Pullback zone to watch: A retracement into the $1,124–$1,151 band (weekly EMA20 to the 23.6% Fibonacci level) would restore a margin of safety without breaking the Stage 2 uptrend and would flip the panel's call to BUY.
- Trend-invalidation level: A weekly close below $1,028 — the 50-week EMA — would break the Stage 2 structure and flip the call to SELL regardless of how strong the business narrative remains.
- Next earnings catalyst: The Q3 2026 report needs to show Mounjaro revenue growth holding above 70% and Foundayo prescriptions continuing their monthly doubling pace; a deceleration in either metric would force a reassessment of the growth trajectory that supports the 42x multiple.
- Competitive tripwire: Approval of a competing oral GLP-1 from Novo Nordisk, Roche, or Amgen before 2028 — or any evidence that net margins are compressing below 30% — would erode the pricing-power assumption that every bull case depends on.
- Balance-sheet checkpoint: Watch whether TTM net debt issuance decelerates below $10 billion in the next two quarters; continued acceleration above the current $15.2 billion pace would signal that the manufacturing build-out is consuming more capital than the growth story can justify.
contact@verdixhq.com · Published 2026-08-22 · Prices as of 2026-08-22 · Time horizon: 3–12 months · No direct position held in LLY · LLY verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.